SpyGlass Pharma, Inc. (NASDAQ:SGP) — Market Cap & Net Worth
Market Cap & Net Worth: SpyGlass Pharma, Inc. (SGP)
SpyGlass Pharma, Inc. (NASDAQ:SGP) has a market capitalization of $823.49 Million ($823.49 Million) as of October 12, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9802 globally and #2669 in its home market, demonstrating a -5.96% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SpyGlass Pharma, Inc.'s stock price $24.92 by its total outstanding shares 33447979 (33.45 Million).
SpyGlass Pharma, Inc. Market Cap History: 2026 to 2026
SpyGlass Pharma, Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $833.52 Million to $833.52 Million (0.00% CAGR). Check today's stock price for SpyGlass Pharma, Inc. for real-time trading data and today's change.
SpyGlass Pharma, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SpyGlass Pharma, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see cash flow conversion of SpyGlass Pharma, Inc. for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of SGP by Market Capitalization
Companies near SpyGlass Pharma, Inc. in the global market cap rankings as of October 12, 2026. See SGP equity financing ratio to understand what proportion of total assets are financed by equity.
Key companies related to SpyGlass Pharma, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $129.29 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $75.50 Billion USD.
- CSL Ltd (AU:CSL): Ranked #448 globally with a market cap of $63.11 Billion USD ( AU$89.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #509 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $129.29 Billion | $510.08 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $75.50 Billion | $746.54 |
| #448 | CSL Ltd | AU:CSL | $63.11 Billion | AU$183.84 |
| #509 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $225.00 |
SpyGlass Pharma, Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, SpyGlass Pharma, Inc.'s market cap moved from $833.52 Million to $ 833.52 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $833.52 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 11th, 2026 the market cap of SpyGlass Pharma, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $823.49 Million USD |
| MoneyControl | $823.49 Million USD |
| MarketWatch | $823.49 Million USD |
| marketcap.company | $823.49 Million USD |
| Reuters | $823.49 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intra… Read more